Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7566889 | 0.85 | NLRP3 (0.65) | NLRP3 | |
| SCHEMBL7567431 | 0.83 | NLRP3 (0.62) | NLRP3 | |
| SCHEMBL462304 | 0.82 | LPAR1 (0.66) | NLRP3 | |
| SCHEMBL8984930 | 0.81 | — | — | |
| SCHEMBL8984914 | 0.81 | NLRP3 (0.60) | NLRP3 | |
| SCHEMBL7566825 | 0.81 | — | — | |
| SCHEMBL7565346 | 0.80 | — | — | |
| SCHEMBL8984939 | 0.80 | NLRP3 (0.55) | NLRP3 | |
| SCHEMBL9723517 | 0.79 | KMT2A (0.61) | NLRP3 | |
| Dimethylamine SCHEMBL9343765 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531576-B2 | Biphenyl derivatives | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1354871-B1 | BIPHENYL DERIVATIVES | POLA PHARMA INC (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20040048909-A1 | N-alkyl-N-(p-substituted-phenyl)benzylamine that is N-substituted with carbocyclic aminocarbonylalkylene, aminocarbonyl, or aminocarbonylaminosulfonyl; ACAT inhibitors; treating e.g.,hypercholesterolemia and atherosclerosis | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1354871-A1 | BIPHENYL DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-0556322-B1 | AMINOSULFONYL UREA ACAT INHIBITORS | WARNER LAMBERT CO (US) | 1996-06-12 | — | — | EP | disclosed |
| EP-0556308-B1 | OXYSULFONYL UREA ACAT INHIBITORS | WARNER LAMBERT CO (US) | 1995-02-01 | — | — | EP | disclosed |
| US-5364882-A | Acyloenzyme a: cholesterol acyltransferase inhibitors, anticholesterol | WARNER-LAMBERT COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| US-5288757-A | Aminosulfonyl urea ACAT inhibitors and a method of lowering blood cholesterol levels therewith | WARNER-LAMBERT COMPANY (US) | 1994-02-22 | — | — | US | disclosed |
| EP-0556308-A1 | OXYSULFONYL UREA ACAT INHIBITORS. | WARNER LAMBERT CO (US) | 1993-08-25 | — | — | EP | disclosed |
| EP-0556322-A1 | AMINOSULFONYL UREA ACAT INHIBITORS. | WARNER LAMBERT CO (US) | 1993-08-25 | — | — | EP | disclosed |
| US-5214206-A | Anticholesterol agents, inhibitors of acylcoenzyme A | WARNER-LAMBERT COMPANY (US) | 1993-05-25 | — | — | US | disclosed |
| US-5198466-A | Acylcoenzyme A Inhibitors | WARNER-LAMBERT COMPANY (US) | 1993-03-30 | — | — | US | disclosed |
| WO-1992008694-A1 | AMINOSULFONYL UREA ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008692-A1 | OXYSULFONYL UREA ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048909-A1 | N-alkyl-N-(p-substituted-phenyl)benzylamine that is N-substituted with carbocyclic aminocarbonylalkylene, aminocarbonyl, or aminocarbonylaminosulfonyl; ACAT inhibitors; treating e.g.,hypercholesterolemia and atherosclerosis | ACAT2, LCAT, NAT1 | NLRP3 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.